Back to Search
CHARLES ERLICHMAN, M.D.
M.D.
Medical Oncology Physician
NPI: 1356311450Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
37347(MN)
Research & Publications (20)
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
PMID 19466875·Expert Opin Investig Drugs·2009
6-review
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
PMID 16710023·J Clin Oncol·2006
3-trial
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
PMID 11212277·Cancer Res·2001
8-other
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.
PMID 11332153·Ann Oncol·2001
3-trial
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
PMID 19415181·Invest New Drugs·2010
3-trial
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
PMID 19470922·J Clin Oncol·2009
3-trial
P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
PMID 18794130·Cancer Res·2008
8-other
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
PMID 18765554·Clin Cancer Res·2008
3-trial
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
PMID 18765823·Mol Cancer Ther·2008
8-other
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
PMID 18278438·Invest New Drugs·2008
3-trial
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
PMID 19047126·Clin Cancer Res·2008
3-trial
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
PMID 19047120·Clin Cancer Res·2008
3-trial
Medical management of pancreatic neuroendocrine tumors.
PMID 18028508·Am J Gastroenterol·2008
6-review
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
PMID 17909811·Cancer Chemother Pharmacol·2008
3-trial
Heat shock protein inhibitors increase the efficacy of measles virotherapy.
PMID 18356818·Gene Ther·2008
8-other
Cisplatin abrogates the geldanamycin-induced heat shock response.
PMID 18852129·Mol Cancer Ther·2008
8-other
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
PMID 17581608·Leukemia·2007
3-trial
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
PMID 17553200·Clin Colorectal Cancer·2007
3-trial
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
PMID 16763792·Cancer Chemother Pharmacol·2007
3-trial
Oxaliplatin in the treatment of colorectal cancer.
PMID 17428157·Expert Opin Drug Metab Toxicol·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1356311450
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile